Literature DB >> 29270377

Medical management of aortic disease in Marfan syndrome.

Syed Usman Bin Mahmood1, Camilo A Velasquez1, Mohammad A Zafar1, Ayman A Saeyeldin1, Adam J Brownstein1, Bulat A Ziganshin1,2, John A Elefteriades1, Sandip K Mukherjee1.   

Abstract

Marfan syndrome (MFS) is a hereditary disorder with numerous pathophysiological effects, some specifically creating elastic dysfunction in cardiovascular organs. Aortic dilatation, dissection and rupture are major concerns in the management of MFS patients. Predilection to form aneurysms is an indication for prophylactic medical management of thoracic aortic aneurysm disease in these patients. The current guidelines describe β-blockers as the standard of care with angiotensin receptor blockers (ARBs) emerging as an equal, if not better alternative. We elaborate current evidence for and against different medical regimens used for the medical management of MFS patients.

Entities:  

Keywords:  Marfan syndrome (MFS); Thoracic aortic aneurysm; aortic dissection; medical management

Year:  2017        PMID: 29270377      PMCID: PMC5721117          DOI: 10.21037/acs.2017.11.09

Source DB:  PubMed          Journal:  Ann Cardiothorac Surg        ISSN: 2225-319X


  32 in total

Review 1.  Medical therapy of thoracic aortic aneurysms: are we there yet?

Authors:  Peter Danyi; John A Elefteriades; Ion S Jovin
Journal:  Circulation       Date:  2011-09-27       Impact factor: 29.690

2.  Atenolol versus losartan in children and young adults with Marfan's syndrome.

Authors:  Ronald V Lacro; Harry C Dietz; Lynn A Sleeper; Anji T Yetman; Timothy J Bradley; Steven D Colan; Gail D Pearson; E Seda Selamet Tierney; Jami C Levine; Andrew M Atz; D Woodrow Benson; Alan C Braverman; Shan Chen; Julie De Backer; Bruce D Gelb; Paul D Grossfeld; Gloria L Klein; Wyman W Lai; Aimee Liou; Bart L Loeys; Larry W Markham; Aaron K Olson; Stephen M Paridon; Victoria L Pemberton; Mary Ella Pierpont; Reed E Pyeritz; Elizabeth Radojewski; Mary J Roman; Angela M Sharkey; Mario P Stylianou; Stephanie Burns Wechsler; Luciana T Young; Lynn Mahony
Journal:  N Engl J Med       Date:  2014-11-18       Impact factor: 91.245

3.  Effect of beta-adrenergic blockade on aortic root rate of dilation in the Marfan syndrome.

Authors:  M A Salim; B S Alpert; J C Ward; R E Pyeritz
Journal:  Am J Cardiol       Date:  1994-09-15       Impact factor: 2.778

4.  Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome.

Authors:  Elif Seda Selamet Tierney; Brian Feingold; Beth F Printz; Sang C Park; Dionne Graham; Charles S Kleinman; C Becket Mahnke; Donna M Timchak; William H Neches; Welton M Gersony
Journal:  J Pediatr       Date:  2007-01       Impact factor: 4.406

5.  ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC).

Authors:  Vera Regitz-Zagrosek; Carina Blomstrom Lundqvist; Claudio Borghi; Renata Cifkova; Rafael Ferreira; Jean-Michel Foidart; J Simon R Gibbs; Christa Gohlke-Baerwolf; Bulent Gorenek; Bernard Iung; Mike Kirby; Angela H E M Maas; Joao Morais; Petros Nihoyannopoulos; Petronella G Pieper; Patrizia Presbitero; Jolien W Roos-Hesselink; Maria Schaufelberger; Ute Seeland; Lucia Torracca
Journal:  Eur Heart J       Date:  2011-08-26       Impact factor: 29.983

6.  Beneficial Outcome of Losartan Therapy Depends on Type of FBN1 Mutation in Marfan Syndrome.

Authors:  Romy Franken; Alexander W den Hartog; Teodora Radonic; Dimitra Micha; Alessandra Maugeri; Fleur S van Dijk; Hanne E Meijers-Heijboer; Janneke Timmermans; Arthur J Scholte; Maarten P van den Berg; Maarten Groenink; Barbara J M Mulder; Aeilko H Zwinderman; Vivian de Waard; Gerard Pals
Journal:  Circ Cardiovasc Genet       Date:  2015-01-22

7.  Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study.

Authors:  Hsin-Hui Chiu; Mei-Hwan Wu; Jou-Kou Wang; Chun-Wei Lu; Shuenn-Nan Chiu; Chun-An Chen; Ming-Tai Lin; Fu-Chang Hu
Journal:  Mayo Clin Proc       Date:  2013-01-12       Impact factor: 7.616

8.  Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model.

Authors:  Yang Yu; Koji Ohmori; Yan Chen; Chubun Sato; Hideyasu Kiyomoto; Kaori Shinomiya; Hiroto Takeuchi; Katsufumi Mizushige; Masakazu Kohno
Journal:  J Am Coll Cardiol       Date:  2004-08-18       Impact factor: 24.094

9.  Angiotensin II blockade and aortic-root dilation in Marfan's syndrome.

Authors:  Benjamin S Brooke; Jennifer P Habashi; Daniel P Judge; Nishant Patel; Bart Loeys; Harry C Dietz
Journal:  N Engl J Med       Date:  2008-06-26       Impact factor: 91.245

10.  Endovascular management of chronic aortic dissection in patients with Marfan syndrome.

Authors:  Ian M Nordon; Robert J Hinchliffe; Peter J Holt; Rob Morgan; Marjan Jahangiri; Ian M Loftus; Matt M Thompson
Journal:  J Vasc Surg       Date:  2009-07-26       Impact factor: 4.268

View more
  4 in total

1.  Pleiotropic activation of endothelial function by angiotensin II receptor blockers is crucial to their protective anti-vascular remodeling effects.

Authors:  Arash Y Tehrani; Zoe White; Lin Wei Tung; Roy Ru Yi Zhao; Nadia Milad; Michael A Seidman; Elodie Sauge; Marine Theret; Fabio M V Rossi; Mitra Esfandiarei; Casey van Breemen; Pascal Bernatchez
Journal:  Sci Rep       Date:  2022-06-13       Impact factor: 4.996

2.  Risk factors of delayed awakening after aortic arch surgery under deep hypothermic circulatory arrest with selective antegrade cerebral perfusion.

Authors:  Zhe-Yan Wang; Wan-Jie Gu; Xuan Luo; Zheng-Liang Ma
Journal:  J Thorac Dis       Date:  2019-03       Impact factor: 2.895

3.  Total arch replacement and frozen elephant trunk for type A aortic dissection after Bentall procedure in Marfan syndrome.

Authors:  Yu Chen; Wei-Guo Ma; Jun Zheng; Yong-Min Liu; Jun-Ming Zhu; Li-Zhong Sun
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

4.  Vascular progenitor cell senescence in patients with Marfan syndrome.

Authors:  Haiwei He; Baoqi Yu; Zipeng Liu; Gen Ye; Wei You; Yimei Hong; Qizhou Lian; Yuelin Zhang; Xin Li
Journal:  J Cell Mol Med       Date:  2019-03-28       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.